Developing a new treatment for cognitive impairment related to Alzheimer's disease

Who could benefit from this research

What this research studies

This research focuses on creating a new therapeutic called PNA5, which is designed to treat cognitive impairment in individuals at risk for Alzheimer's disease-related dementias and vascular contributions to cognitive impairment and dementia. The approach involves formulating an extended-release subcutaneous injection of PNA5 and conducting toxicology studies to ensure its safety. The therapy aims to improve brain blood flow and reduce inflammation by targeting specific receptors in the brain. Patients participating in this research may help advance a novel treatment that could address a significant unmet need in dementia care.

Why it matters

Where this research is happening

• Proneurogen, INC.
  Tucson, United States Active

Researchers

• Principal investigator: Riley, Jeremy — Proneurogen, INC.
• Study coordinator: Riley, Jeremy

Related research

Other NIH-funded projects on the same topics.

• Global picture of dementia risk and memory loss across the world

  A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.

  NIH research University of New South Wales · Sydney, Australia · NIH-11603263

• PNA5 for VCID and Alzheimer's Dementias: A first-in-human safety study

  A first-in-human trial tests a new drug, PNA5, to see if it is safe and tolerable for adults with vascular cognitive impairment and Alzheimer's-related dementias.

  NIH research University of Arizona · Tucson, United States · NIH-11442935

• Global picture of dementia and Alzheimer’s risk across populations

  A large international effort gathers health data from many cohorts to understand what increases or lowers the risk of dementia and Alzheimer's disease around the world.

  NIH research University of New South Wales · Sydney, Australia · NIH-11417899

• Global patterns of cognitive impairment and Alzheimer's dementia

  Bringing together memory-study data from around the world to find lifestyle and environmental factors people can change to lower the risk of Alzheimer's and related dementias.

  NIH research University of New South Wales · Sydney, Australia · NIH-11416183

• Extreme longevity and brain health in centenarians and families

  This grant studies why some people live to 100 with strong thinking skills and how genes and biomarkers relate to Alzheimer’s disease and related dementias, aiming to help others stay cognitively healthy as they age.

  NIH research Translational Genomics Research Inst · Phoenix, United States · NIH-11399386

• A brain-boosting peptide to help people at risk of vascular dementia and Alzheimer’s disease

  A new drug-like peptide (PNA5) is being studied to reduce brain inflammation and improve blood flow in people at risk for vascular dementia and Alzheimer's-related dementia.

  NIH research University of Arizona · Tucson, United States · NIH-11396379

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.